Amylyx Pharmaceuticals (AMLX) Income towards Parent Company (2021 - 2026)

Amylyx Pharmaceuticals' Income towards Parent Company history runs 6 years deep, the most recent figure standing at -$91.0 million for Q1 2026.

• On a quarterly basis, Income towards Parent Company fell 153.29% year-over-year to -$91.0 million in Q1 2026; TTM through Mar 2026 was -$199.8 million, a 28.23% decrease from a year earlier, with the FY2025 full-year figure at -$144.7 million, up 39.36% from the prior year.
• Income towards Parent Company slipped to -$91.0 million in Q1 2026 per AMLX's latest filing, from -$33.0 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at $25.5 million in Q4 2024 and bottomed at -$118.8 million in Q1 2024.
• The 5-year median for Income towards Parent Company is -$41.4 million (2025), against an average of -$36.9 million.
• Biggest YoY gain for Income towards Parent Company was 845.87% in 2024; the steepest drop was 7652.0% in 2024.
• Year by year, Income towards Parent Company stood at -$43.8 million in 2022, then surged by 106.16% to $2.7 million in 2023, then surged by 845.87% to $25.5 million in 2024, then plunged by 229.36% to -$33.0 million in 2025, then plunged by 175.61% to -$91.0 million in 2026.
• Per Business Quant, the three latest AMLX Income towards Parent Company figures stand at -$91.0 million (Q1 2026), -$33.0 million (Q4 2025), and -$34.4 million (Q3 2025).